Dose Insider / Glossary / Wegovy

WegovyWhat it is, who it is for and how it is taken

Updated November 20, 2026 路 4 min read 路 WEGOVY prescribing information, revised June 2026

Wegovy is a brand of semaglutide made by Novo Nordisk for weight management, sold as a once-weekly injection and as a once-daily tablet. Used with a reduced-calorie diet and more physical activity, it is approved to lower body weight and keep it off, and to cut the risk of heart attack, stroke and cardiovascular death in adults with heart disease and excess weight.

14.9%Injection, 68 weeks, 2.4 mg, weight lost in the label trials
Weight lost in the label trials% of starting weight, injection and tabletINJECTION, 68 WEEKS2.4 mg14.9%Placebo2.4%TABLET, 64 WEEKS25 mg13.6%Placebo2.4%Weight lost in the labeltrials% of starting weight, injection and tabletINJECTION, 68 WEEKS2.4 mg14.9%Placebo2.4%TABLET, 64 WEEKS25 mg13.6%Placebo2.4%

In SELECT, 6.5% had a heart attack, stroke or cardiovascular death, against 8% on placebo.

On this page

The injection is also approved for teenagers aged 12 and older with obesity, and for a scarring form of fatty liver disease called MASH.1

What it is

Wegovy contains the same molecule as Ozempic. Semaglutide copies the gut hormone GLP-1 and acts on its receptor, which is why it belongs to the class called GLP-1 receptor agonists. The two brands differ in what they are approved for and how high the dose goes. The Ozempic injection treats type 2 diabetes and stops at 2 mg a week. Wegovy is approved for weight and heart risk and goes to 2.4 mg, or 7.2 mg for some adults under the name Wegovy HD.1,2 The label gives 2017 as the first U.S. approval of semaglutide.

The tablet works differently on the way in. It is made with an absorption enhancer called SNAC, and only about 1% to 2% of the semaglutide in a tablet reaches the blood, which is why the tablet doses are much larger than the injected ones.1

Who the label approves it for

Each use is listed on the label as an addition to a reduced-calorie diet and increased physical activity.1

How the dose climbs

The injection starts at 0.25 mg once a week for weeks 1 to 4, then 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12 and 1.7 mg for weeks 13 to 16. From week 17 the maintenance dose for weight in adults is 2.4 mg, the recommended one, or 1.7 mg. An adult who has tolerated 2.4 mg for at least 4 weeks and needs more weight reduction may go up to 7.2 mg. The shot goes under the skin of the abdomen, thigh or upper arm on the same day each week, at any time of day.1

The tablet starts at 1.5 mg a day for days 1 to 30, then 4 mg, 9 mg and 25 mg from day 91. It is taken in the morning on an empty stomach with up to 4 ounces of plain water, followed by a wait of at least 30 minutes before food, drinks or other pills.1 Our pages on the Wegovy dosing schedule and on how to take the Wegovy pill turn both ladders into dates.

What it did in trials

In the label's main 68-week weight trial in adults without diabetes, who started at an average of 105.4 kg, the 2.4 mg injection lowered weight by 14.9% against 2.4% on placebo. A loss of at least 15% was reached by 47.9% on Wegovy against 4.8% on placebo, and a loss of at least 20% by 30.2% against 1.7%.1

The 25 mg tablet lowered weight by 13.6% at week 64, against 2.4% on placebo.1 In teenagers with obesity, body mass index fell by 16.1% at week 68 on the injection, while it rose by 0.6% on placebo.1

The heart trial, SELECT, enrolled 17,604 adults with cardiovascular disease and excess weight. A first heart attack, stroke or cardiovascular death occurred in 6.5% on Wegovy and 8% on placebo, a hazard ratio of 0.80, or about a fifth lower risk.1

Side effects and warnings

In the adult weight trials, nausea was reported by 44% on the 2.4 mg injection against 16% on placebo, diarrhea by 30% against 16%, vomiting by 24% against 6% and constipation by 24% against 11%.1 Most of these start during the climb in dose; our page on nausea on a GLP-1 covers what helps.

Like Ozempic, Wegovy carries a boxed warning about thyroid C-cell tumors seen in rodents and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. The label also warns about pancreatitis, gallbladder disease, low blood sugar in people with diabetes, kidney injury from fluid loss, a faster heart rate and aspiration during anesthesia or deep sedation. It advises stopping the medicine at least 2 months before a planned pregnancy.1

Wegovy in eight lines

FactWegovy
Active ingredientSemaglutide
MakerNovo Nordisk
FormsWeekly injection, daily tablet
Injection doses0.25 mg to start, 2.4 mg usual, up to 7.2 mg
Tablet doses1.5 mg to start, 25 mg from day 91
Approved forWeight, heart risk, MASH (injection)
Youngest age12, injection only
Before a planned pregnancyStop at least 2 months ahead

WEGOVY prescribing information, revised June 2026.1

Ozempic and Rybelsus are the other semaglutide brands, both for type 2 diabetes. Zepbound is the tirzepatide brand approved for the same weight use. Our pages compare Ozempic and Wegovy label by label and set out what Wegovy costs with and without insurance.

Sources

  1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2, 3, 5, 6.1, 8, 12 and 14. accessdata.fda.gov
  2. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1 and 2. accessdata.fda.gov

Related analyses

Log each Wegovy dose and your weight, and see the trend on one chart.

Open Dose Insider